Staging of idiopathic pulmonary fibrosis: Past, present and future

European Respiratory Review

Volumn 23, Issue 132, 2014, Pages 220-224

  Kolb, Martin ^a   Collard, Harold R ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER;

AGE; DISEASE SEVERITY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GAP INDEX; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE STAGING SYSTEM; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITALIZATION; HUMAN; LUNG DIFFUSION CAPACITY; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; STAGING; AGED; DECISION SUPPORT SYSTEM; FEMALE; HISTORY; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TRENDS; VITAL CAPACITY;

AGE FACTORS; AGED; DECISION SUPPORT TECHNIQUES; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DIFFUSING CAPACITY; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; VITAL CAPACITY;

EID: 84901817527     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00002114     Document Type: Review

References (26)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137: 129-137.
3. Ley B, Collard HR, King TE Jr, et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
4. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643.
5. Gonnella JS, Hornbrook MC, Louis DZ. Staging of disease. A case-mix measurement. JAMA 1984; 251: 637-644.
6. st Edn. Orange Park, Editorial Rx Press, 2009.
7. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, WHO, 2007.
8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf Date last updated: December 2013. Date last accessed: January 17, 2014.
9. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, et al. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005; 6: 98.
10. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-542.
11. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
12. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
13. King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis. Scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
14. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
15. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
16. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
17. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
18. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
19. Mogulkoc N, Brutsche MH, Bishop PW, et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164: 103-108.
20. Egan JJ, Martinez FJ, Wells AU, et al. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005; 60: 270-273.
21. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
22. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
23. Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008; 246: 935-940.
24. Battista G, Zompatori M, Fasano L, et al. Progressive worsening of idiopathic pulmonary fibrosis. High resolution computed tomography (HRCT) study with functional correlations. Radiol Med 2003; 105: 2-11.
25. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 67-76.
26. Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012; 18: 441-446.